» Articles » PMID: 35454328

Cardiovascular Disorder After Cardiotoxic Non-Hodking's Lymphoma Treatment: A Case Report

Overview
Publisher MDPI
Specialty General Medicine
Date 2022 Apr 23
PMID 35454328
Authors
Affiliations
Soon will be listed here.
Abstract

The non-Hodgkin's lymphomas are a diverse group of lymphoid neoplasms that collectively rank fifth in cancer incidence and mortality. Patients treated with mediastinal radiotherapy and/or anthracycline-containing chemotherapy are known to have increased risks of coronary heart disease, valvular heart disease, and heart failure. This may be the result of cancer treatment cardiotoxicity or may be due to accelerated development of cardiovascular disease. We presented 41-year-old male who was admitted to the hospital because of congestive heart failure. He has a medical history of non-Hodgkin's lymphoma treated with anthracycline-based chemotherapy and mediastinal radiotherapy almost 20 years ago. Echocardiography showed significant aortic valve stenosis, thickened and fibrotic pericardium. Coronary angiography showed diffuse three-vessel coronary artery disease. The patient was referred for surgical treatment. Aortic valve replacement, coronary artery bypass grafting and pericardiectomy were successfully performed, symptoms of heart failure reduced.

References
1.
Tajiri K, Aonuma K, Sekine I . Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients. Jpn J Clin Oncol. 2017; 47(8):678-682. DOI: 10.1093/jjco/hyx068. View

2.
Salz T, Zabor E, de Nully Brown P, Oksberg Dalton S, Raghunathan N, Matasar M . Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors. J Clin Oncol. 2017; 35(34):3837-3843. PMC: 5707207. DOI: 10.1200/JCO.2017.72.4211. View

3.
Zamorano J, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M . 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of.... Eur Heart J. 2016; 37(36):2768-2801. DOI: 10.1093/eurheartj/ehw211. View

4.
Volkova M, Russell 3rd R . Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev. 2012; 7(4):214-20. PMC: 3322439. DOI: 10.2174/157340311799960645. View

5.
Singh R, Shaik S, Negi B, Rajguru J, Patil P, Parihar A . Non-Hodgkin's lymphoma: A review. J Family Med Prim Care. 2020; 9(4):1834-1840. PMC: 7346945. DOI: 10.4103/jfmpc.jfmpc_1037_19. View